Pharmacology · Cardiovascular

Hypertension with Comorbid Cardiovascular Disease

Compelling indications, mechanism-driven agent selection, and integrated targets across comorbidities

Heart failure with reduced ejection fraction now requires four pillars of guideline-directed medical therapy simultaneously: sacubitril-valsartan (preferred over ACE inhibitor by PARADIGM-HF with a 20 percent reduction in cardiovascular death and heart failure hospitalization), one of exactly three proven beta-blockers (carvedilol, metoprolol succinate, bisoprolol), a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor — with the critical rule that non-dihydropyridine CCBs are absolutely contraindicated while amlodipine is safe.
Post-myocardial infarction pharmacotherapy addresses remodeling rather than blood pressure alone: ACE inhibitors or ARBs are mandatory when ejection fraction is at or below 40 percent, beta-blockers reduce sudden death and reinfarction, and eplerenone started within 3 to 14 days of MI (EPHESUS) reduces all-cause mortality by 15 percent in patients already on ACE inhibitor and beta-blocker — with the J-curve caution that diastolic pressure should not be reduced below 65 to 70 mm Hg.
Atrial fibrillation and hypertension share the same RAAS inhibitor logic: beta-blockers or non-dihydropyridine CCBs provide rate control alongside blood pressure lowering (never combined due to complete heart block risk), while RAAS inhibitors prevent upstream atrial remodeling — the LIFE trial showed losartan significantly reduced new-onset atrial fibrillation versus atenolol in hypertensive patients with left ventricular hypertrophy.
Aortic dissection demands the opposite sequence from most hypertensive emergencies: beta-blocker must come first to reduce heart rate and dP/dt before any vasodilator is added, because vasodilator-induced reflex tachycardia increases aortic wall stress and propagates the dissection; the acute target is systolic 100 to 120 mm Hg with heart rate below 60 bpm.
Stable coronary artery disease and peripheral arterial disease share ACE inhibitor or ARB secondary prevention evidence (HOPE, EUROPA for CAD; HOPE in PAD populations), with beta-blockers reserved for anti-ischemic benefit in CAD and used cautiously in PAD where non-selective agents may worsen claudication.

Abbreviations: HFrEF = heart failure with reduced ejection fraction · HFpEF = heart failure with preserved ejection fraction · GDMT = guideline-directed medical therapy · MRA = mineralocorticoid receptor antagonist · SGLT2 = sodium-glucose cotransporter 2 · CCB = calcium channel blocker · DHP = dihydropyridine · Non-DHP = non-dihydropyridine · ACEi = angiotensin converting enzyme inhibitor · ARB = angiotensin receptor blocker · RAAS = renin-angiotensin-aldosterone system · EF = ejection fraction · MI = myocardial infarction · CAD = coronary artery disease · AF = atrial fibrillation · PAD = peripheral arterial disease · LVH = left ventricular hypertrophy · TGF-beta = transforming growth factor beta · dP/dt = rate of change of aortic pressure · IV = intravenous · SBP = systolic blood pressure

HFrEF — Four-Pillar Guideline-Directed Medical Therapy

1 Angiotensin Pathway Inhibition

Sacubitril-valsartan (preferred): PARADIGM-HF — 20% reduction in cardiovascular death and HF hospitalization vs enalapril

ACEi or ARB when sacubitril-valsartan not tolerated

WARNING: Never combine sacubitril-valsartan + ACEi — angioedema risk; 36-hour washout required

2 Beta-Blocker (3 Proven Agents Only)

Carvedilol: COPERNICUS — 35% mortality reduction in severe HFrEF

Metoprolol succinate: MERIT-HF — 34% mortality reduction

Bisoprolol: CIBIS-II — 34% mortality reduction

Start lowest dose when stable; never initiate in acute decompensation

3 Mineralocorticoid Receptor Antagonist

Spironolactone: RALES — 30% mortality reduction (severe HFrEF)

Eplerenone: EMPHASIS-HF — 37% reduction in cardiovascular mortality and HF hospitalization (mild HFrEF)

Contraindicated: K+ above 5.0; creatinine above 2.5 (men) or 2.0 (women); eGFR below 30

4 SGLT2 Inhibitor

Dapagliflozin: DAPA-HF — 26% reduction in composite of cardiovascular death, HF hospitalization, or urgent HF visit regardless of diabetes status

Empagliflozin: EMPEROR-Reduced — Class I GDMT

Additional antihypertensive effect: 3–5 mm Hg systolic reduction

The Critical CCB Distinction in Heart Failure

Non-DHP CCBs (verapamil, diltiazem): ABSOLUTELY CONTRAINDICATED in HFrEF — negative inotropy worsens systolic function and outcomes. Amlodipine (DHP CCB): SAFE in HFrEF — PRAISE trials confirmed no worsening of HF outcomes; amlodipine is the ONLY CCB that can safely be added to HFrEF GDMT for additional BP control.

Compelling Indications — Preferred Agents by Cardiovascular Comorbidity

Agent Selection Matters as Much as the Blood Pressure Target

Mechanism-Driven Drug Selection Across Comorbidities

Comorbidity	Priority Drug Classes	Avoid / Caution
HFrEF	Sacubitril-valsartan or ACEi or ARB + beta-blocker (carvedilol, metoprolol succinate, bisoprolol) + MRA + SGLT2 inhibitor; amlodipine safe for additional BP control; target below 130/80	Non-DHP CCBs — absolutely contraindicated
HFpEF	RAAS inhibitors for BP and LVH regression; SGLT2 inhibitors (Class I or IIa — EMPEROR-Preserved, DELIVER); finerenone (FINEARTS-HF 2024); diuretics for symptoms; target below 130/80	No single class proven to reduce mortality — avoid over-diuresis
Post-MI (EF at or below 40%)	ACEi or ARB (mandatory); beta-blocker; eplerenone (EPHESUS) if EF at or below 40% + HF symptoms or diabetes; target below 130/80; avoid diastolic below 65–70	Non-DHP CCBs and immediate-release nifedipine contraindicated if EF reduced
Stable CAD	Beta-blocker (anti-ischemic + antihypertensive); amlodipine (CAMELOT evidence); ACEi or ARB for secondary prevention (HOPE, EUROPA); target below 130/80; avoid diastolic below 65–70 (J-curve)	Non-DHP CCB + beta-blocker combination (AV block); short-acting DHP CCBs (reflex tachycardia)
Atrial fibrillation	Beta-blocker (rate control + antihypertensive — carvedilol if concurrent HFrEF); non-DHP CCB if no HFrEF (diltiazem preferred); RAAS inhibitor for upstream AF prevention (LIFE trial — losartan vs atenolol); SBP below 130 on anticoagulation	Non-DHP CCB absolutely contraindicated in HFrEF; never combine non-DHP CCB + beta-blocker
Aortic dissection (acute)	Beta-blocker FIRST (esmolol or labetalol IV; target heart rate below 60); add vasodilator only after rate controlled; target systolic 100–120; chronic: SBP below 120–130, beta-blocker + ACEi or ARB; Marfan: add losartan (TGF-beta inhibition)	Vasodilator without prior beta-blocker — reflex tachycardia increases dP/dt and propagates dissection
Peripheral arterial disease	ACEi or ARB (HOPE trial evidence in PAD populations); cardioselective beta-blockers acceptable with cardiac indication; amlodipine (may modestly benefit claudication); target below 130/80; use higher-arm BP for monitoring	Non-selective beta-blockers may worsen claudication

Post-MI Regimen & Atrial Fibrillation Rate Control

Prevention of Remodeling and Mortality Reduction

Post-Myocardial Infarction Pharmacotherapy

ACEi or ARB (mandatory if EF at or below 40% or anterior MI): prevents infarct expansion, ventricular remodeling, and progression to HF; GISSI-3, ISIS-4, SAVE, AIRE — mortality benefit confirmed; VALIANT — valsartan non-inferior to captopril
Beta-blocker: reduces ventricular arrhythmias, sudden death, and reinfarction; carvedilol, metoprolol succinate, or bisoprolol when EF reduced
Eplerenone (EPHESUS — START WITHIN 3–14 DAYS): EF at or below 40% + HF symptoms or diabetes + already on ACEi and beta-blocker → 15% reduction in all-cause mortality; 13% reduction in cardiovascular mortality and morbidity
Target BP: below 130/80 mm Hg; avoid diastolic below 65–70 mm Hg (J-curve — coronary perfusion is diastole-dependent)

Rate Control Agent Selection and Upstream Prevention

Atrial Fibrillation & Hypertension

Beta-blocker (rate control + antihypertensive): first-line in most patients; carvedilol serves dual role as rate control agent and GDMT when HFrEF coexists
Non-DHP CCB (diltiazem or verapamil): effective rate control + antihypertensive; absolutely contraindicated in HFrEF; NEVER combine with beta-blocker (complete heart block); diltiazem preferred (fewer drug interactions, less constipation than verapamil)
RAAS inhibitors for upstream AF prevention: block angiotensin II-mediated atrial fibrosis; reduce left atrial size and electrical remodeling; LIFE trial — losartan significantly reduced new-onset AF vs atenolol in hypertensive LVH
Anticoagulation by CHA₂DS₂-VASc score; hypertension adds 1 point; target SBP below 130 mm Hg on anticoagulation to reduce intracranial hemorrhage risk

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Whelton PK, Carey RM, Aronow WS, et al.	2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults	J Am Coll Cardiol. 2018;71(19):e127–e248
Mancia G, Kreutz R, Brunstrom M, et al.	2023 ESH guidelines for the management of arterial hypertension	J Hypertens. 2023;41(12):1874–2071
Heidenreich PA, Bozkurt B, Aguilar D, et al.	2022 AHA/ACC/HFSA guideline for the management of heart failure	J Am Coll Cardiol. 2022;79(17):e263–e421
McMurray JJ, Packer M, Desai AS, et al.	Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF)	N Engl J Med. 2014;371(11):993–1004
Packer M, Coats AJ, Fowler MB, et al.	Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS)	N Engl J Med. 2001;344(22):1651–1658
MERIT-HF Study Group	Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF)	Lancet. 1999;353(9169):2001–2007
CIBIS-II Investigators and Committees	The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial	Lancet. 1999;353(9146):9–13
Pitt B, Zannad F, Remme WJ, et al.	The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES)	N Engl J Med. 1999;341(10):709–717
Zannad F, McMurray JJ, Krum H, et al.	Eplerenone in patients with systolic heart failure and mild symptoms (EMPHASIS-HF)	N Engl J Med. 2011;364(1):11–21
McMurray JJV, Solomon SD, Inzucchi SE, et al.	Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF)	N Engl J Med. 2019;381(21):1995–2008
O'Gara PT, Kushner FG, Ascheim DD, et al.	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction	J Am Coll Cardiol. 2013;61(4):e78–e140
Pitt B, Remme W, Zannad F, et al.	Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (EPHESUS)	N Engl J Med. 2003;348(14):1309–1321
Yusuf S, Sleight P, Pogue J, et al.	Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE trial)	N Engl J Med. 2000;342(3):145–153
Dahlof B, Devereux RB, Kjeldsen SE, et al.	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)	Lancet. 2002;359(9311):995–1003
Pieske B, Tschope C, de Boer RA, et al.	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm	Eur Heart J. 2019;40(40):3297–3317